- Home
- CR vs EXEL Comparison
CR vs EXEL Comparison
Compare CR & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | EXEL |
|---|---|---|
| Founded | 1855 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 11.4B |
| IPO Year | 2022 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CR | EXEL |
|---|---|---|
| Price | $223.04 | $54.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $226.20 | $46.50 |
| AVG Volume (30 Days) | 469.7K | ★ 2.4M |
| Earning Date | 04-27-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | 23.96 | ★ 57.95 |
| EPS | ★ 1.14 | 0.79 |
| Revenue | ★ $2,305,000,000.00 | $452,477,000.00 |
| Revenue This Year | $27.98 | $13.61 |
| Revenue Next Year | $5.76 | $13.13 |
| P/E Ratio | $193.41 | ★ $68.70 |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $159.58 | $33.76 |
| 52 Week High | $226.46 | $55.91 |
Technical Indicators
Market Signals| Indicator | CR | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 73.41 | 64.09 |
| Support Level | $173.83 | $40.17 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 6.31 | 1.53 |
| MACD | 1.12 | 0.06 |
| Stochastic Oscillator | 86.09 | 74.95 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.